2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

508. Bone Marrow Failure: Acquired: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Cell Expansion, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Biological Therapies, Gene Therapy, Non-Biological Therapies, Pharmacology, Adverse Events, Biological Processes, Pathogenesis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Clinical Practice (Health Services and Quality), Quality Improvement, Diseases, Bone Marrow Failure Syndromes, Acquired Marrow Failure Syndromes , Aplastic Anemia, Paroxysmal Nocturnal Hemoglobinuria, Genetic Disorders, Immunology, Autoimmune Disorders, Immunodeficiency, Neutropenia, Infectious Diseases, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Patient-Reported Outcomes, Real-World Evidence, Study Population, Human, Adult, Pediatric, Young Adult, Animal Model
PAPER

3178 Retrospective single-cell lineage tracing and longitudinal profiling elucidate origin, clonal dynamics and potential therapeutic interventions in patients with vexas syndrome

Laura Alessandrini, Martina Fiumara2, Stefano Beretta3, Anaïs van Leuwen4, Elisa Diral5, Gregorio Maria Bergonzi, MD6, Corrado Campochiaro7, Alessandro Tomelleri8, Pamela Quaranta9, Luca Basso-Ricci10, Sabine Visser11, Roberta Alfieri12, Markus Van Roosmalen13, Chiara Gaddoni14, Luisa Albano15, Alessandro Aiuti, MD, PhD16, Raffaella Molteni17, Simone Cenci18, Ivan Merelli, PhD19, Lorenzo Dagna20, Fabio Ciceri, MD21, Serena Scala, PhD22, Ruben Van Boxtel, PhD23, Luigi Naldini, MD24, Samuele Ferrari Jr, PhD25
1 San Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute, Milan, Italy, Vita-Salute San Raffaele University, Milan, Italy
2 San Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute, Milan, Italy
3 San Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute, Milan, Italy
4 Oncode Institute, Utrecht, Netherlands, Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands
5 Unit of Hematology and Bone Marrow Transplantation, IRCCS San Raffaele Scientific Institute, Milan, Italy
6 San Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute, Milan, Italy, Unit of Hematology and Bone Marrow Transplantation, IRCCS San Raffaele Scientific Institute, Milan, Italy, Vita-Salute San Raffaele University, Milan, Italy
7 Unit of Immunology, Rheumatology, Allergy and Rare diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy, Vita-Salute San Raffaele University, Milan, Italy
8 Unit of Immunology, Rheumatology, Allergy and Rare diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy, Vita-Salute San Raffaele University, Milan, Italy
9 San Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute, Milan, Italy
10 San Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute, Milan, Italy
11 Oncode Institute, Utrecht, Netherlands, Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands
12 National Research Council, Institute for Biomedical Technologies, Segrate, Italy, San Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute, Milan, Italy
13 Oncode Institute, Utrecht, Netherlands, Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands
14 San Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute, Milan, Italy
15 San Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute, Milan, Italy
16 San Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute, Milan, Italy, Vita-Salute San Raffaele University, Milan, Italy
17 Inflammation Fibrosis and Ageing Initiative (INFLAGE), Division of Genetics and Cell Biology, IRCCS San Raffaele Scientific Institute, Milan, Italy, Vita-Salute San Raffaele University, Milan, Italy
18 Inflammation Fibrosis and Ageing Initiative (INFLAGE), Division of Genetics and Cell Biology, IRCCS San Raffaele Scientific Institute, Milan, Italy, Vita-Salute San Raffaele University, Milan, Italy
19 National Research Council, Institute for Biomedical Technologies, Segrate, Italy, San Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute, Milan, Italy
20 Unit of Immunology, Rheumatology, Allergy and Rare diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy, Vita-Salute San Raffaele University, Milan, Italy
21 Unit of Hematology and Bone Marrow Transplantation, IRCCS San Raffaele Scientific Institute, Milan, Italy, Vita-Salute San Raffaele University, Milan, Italy
22 San Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute, Milan, Italy
23 Oncode Institute, Utrecht, Netherlands, Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands
24 San Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute, Milan, Italy, Vita-Salute San Raffaele University, Milan, Italy
25 San Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute, Milan, Italy, Vita-Salute San Raffaele University, Milan, Italy

VEXAS is an acquired genetic disease at the intersection between immune dysregulation, clonal hematopoiesis, and bone marrow failure. Three fundamental questions remain unanswered: when does the UBA1 mutation arise, how and why does the clone expand over decades, and how do different mutations and treatments differentially reshape hematopoiesis? Moreover, current therapies provide symptomatic relief, but have limited efficacy; allogenic HSPCs transplantation can be curative but have high risk and morbidity. Here we integrate retrospective single-cell lineage tracing with longitudinal single-cell profiling to decipher the trajectory of VEXAS from mutation origin to clonal dominance, while exploring the rationale for autologous HSPC gene therapy.
We performed immunophenotypic, transcriptional, and phylogenetic profiling of a VEXAS cohort using multiparametric flow cytometry, longitudinal single-cell RNA sequencing (scRNA-seq) on bone marrow cells, and single-cell whole-genome sequencing (scWGS) of HSPCs for retrospective clonal reconstruction. In parallel, a lentiviral (LV) gene therapy strategy was evaluated in VEXAS-like models generated by base editing.
Immunophenotyping of 16 patients consistently revealed marked depletion of primitive HSPCs and strong myeloid bias relative to age- and sex-matched controls. The severity of these alterations was mutation-specific, as Thr and Val mutations caused more profound hematopoietic alterations than Leu. Thr variant specifically depleted proerythroblasts, NK/NKT cells, and primitive HSPCs, whereas Val variant drove myeloid skewing of HSPCs and reduction of B-cell populations. scRNA-seq further resolved genotype-specific transcriptional programs, linking Thr and Leu to heightened inflammation and Thr and Val to impaired erythropoiesis. Treatment stratification revealed only modest immunophenotypic differences (reduced primitive HSPCs under prednisone alone and myeloid skewing with combined prednisone/IL-JAK inhibition) suggesting current therapies do not fundamentally reverse hematopoietic remodeling.
Longitudinal scRNA-seq profiling of three patients under azacitidine or azacitidine+ruxolitinib treatment uncovered a dissociation between peripheral and central disease compartments: peripheral blood inflammation and VAF declined during treatment, yet bone marrow HSPCs VAF remained elevated or rebounded after discontinuation, pointing to clonal re-expansion from the stem cell reservoir as a driver of relapse. This disconnect between clinical and molecular remission may suggest that durable disease control requires targeting the clone.
Retrospective lineage tracing by scWGS on three patients showed that UBA1-mutant HSPCs form private clonal clades phylogenetically distinct from wild-type hematopoiesis, consistent with descent from a common ancestor. Strikingly, mutational timing and signature analyses placed the origin of UBA1 mutations in early life, likely during adolescence, suggesting that the mutation expands silently over decades. Mutational signature and evolutionary selection pressure analyses are ongoing to identify mechanisms that shaped clonal dynamics over time, and will be reported.
Finally, LV-mediated expression of UBA1b partially rescued clonogenic and erythroid potential at two vector copies per cell in VEXAS-like HSPCs. Preliminary transplantation experiments in the VEXAS model showed improved hematopoietic reconstitution.
Our data suggest that UBA1 mutations arise silently early in life and expand over decades to reshape hematopoiesis in a mutation-specific manner. The limited effect of current therapies on hematopoietic composition in patients support the rationale for clone-targeting therapies. Preliminary experiments support further investigation of a lentiviral UBA1b gene addition therapy as potential therapeutic strategy.

Laura Alessandrini: No relevant conflicts of interest to declare.